M3, Inc. (MTHRY) Stock Price & Analysis
M3, Inc. (MTHRY) — price $5.35 (0.00%), as of the Nov 19, 2026 trading session; market cap $7.11B.
Educational signal · not a buy or sell recommendation · How to read this
M3, Inc. · MTHRY · Healthcare · Medical - Healthcare Information Services
M3, Inc., established in Tokyo, Japan, in 2000, and formerly known as So-netM3, Inc. until its rebranding in January 2010, specializes in delivering a broad range of internet-based services, primarily targeting physicians…
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $5.35 | |
| Change on the day | 0.00% | |
| 52-week range | $3.97–$8.84 | |
| Market capitalisation | $7.11B | — |
| Price / earnings (trailing) | 25.29 | |
| Shares traded on the day | 366 | |
| Beta (volatility vs the S&P 500) | 0.48 | |
| Dividends per share (last 12 months) | $0.04 | |
| Dividend yield (last 12 months) | 0.74% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results
- · Earnings results
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Other perspectives
Council score for M3 (MTHRY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 1, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Oct 1, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Oct 1, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is M3 (MTHRY), and what does it report?
Short answer
M3, Inc., established in Tokyo, Japan, in 2000, and formerly known as So-netM3, Inc. until its rebranding in January 2010, specializes in delivering a broad range of internet-based services, primarily targeting physicians… Healthcare / Medical Healthcare Information Services Headquarters: Akasaka Intercity, Tokyo, TY, 107-0052, JP. It employs 17,010 people and is led by Itaru Tanimura. In Q2 FY2027 it reported revenue of ¥91.68B and net income of ¥10.92B. The market values it at $7.11B.
What do the latest results show for M3 (MTHRY)?
Short answer · as of
The most recent reported quarter, Q2 FY2027, carried revenue of ¥91.68B.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $554.30M Apr 30, 2026
- Latest report · revenue estimate
- $565.36M Apr 30, 2026
- Latest report · revenue vs estimate
- Below estimate Apr 30, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Apr 30, 2026 | $554.30M | $565.36M | $0.0354 | Not available |
| Feb 9, 2026 | $607.46M | $609.56M | $0.0908 | Not available |
| Oct 28, 2025 | $574.25M | $559.83M | $0.0544 | Not available |
| Jul 28, 2025 | $595.24M | $570.08M | $0.0004 | Not available |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2027 | ¥91.68B | ¥10.92B | ¥8.18 (diluted) |
| Q1 FY2027 | ¥91.29B | ¥9.19B | ¥6.88 (diluted) |
| Q4 FY2026 | ¥88.57B | ¥7.59B | ¥5.66 (diluted) |
| Q3 FY2026 | ¥95.20B | ¥19.28B | ¥14.21 (diluted) |
What are the financial strengths and risks for M3 (MTHRY)?
Short answer · as of
The distress and quality screens read Altman Z 5.30 · Piotroski F 5. Trailing ratios: ROE 11.3% · ROA 7.0% · current ratio 2.44 · earnings yield 3.8%.
What should you watch next at M3 (MTHRY)?
Research dated 2026-09-13.
Investors monitoring the stock should track whether actual revenue can close the gap with analyst projections, as recent periods have shown actual results trailing consensus estimates.
Another key observation point is the progression of the international segment, particularly the European and American practitioner networks. Continued scaling in those overseas portals is required to validate the strategy of replicating its domestic pharmaceutical marketing success in foreign regulatory environments.
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
How is M3 scored?
Research dated 2026-09-13.
Unlike conventional digital advertising networks that monetize broad consumer traffic, this platform generates value exclusively through a highly restricted audience of medical practitioners.
When compared to traditional contract research organizations or healthcare staffing firms, this business derives its advantage from a captive user base, allowing it to source clinical trial participants and job candidates directly from its own portals. This integrated approach reduces acquisition costs significantly compared to standalone medical recruiters.
| Company | Price | Market value | Score |
|---|---|---|---|
| $58.79 Nov 19, 2026 | $12.2B | — Model unavailable | |
| $0.64 Nov 19, 2026 | $10.2B | — Model unavailable | |
| $1.46 Nov 13, 2026 | $8.46B | — Model unavailable | |
| $53.40 Nov 19, 2026 | $11.3B | — Model unavailable | |
| $12.72 Nov 19, 2026 | $8.66B | — Model unavailable | |
| $57.07 Nov 18, 2026 | $7.51B | — 5-pillar · not comparable | |
| $97.31 Nov 18, 2026 | $8.05B | — 5-pillar · not comparable | |
| $114.53 Nov 18, 2026 | $9.31B | — 5-pillar · not comparable | |
| $29.61 Nov 19, 2026 | $5.28B | — 5-pillar · not comparable | |
| $63.62 Nov 18, 2026 | $11.6B | — 5-pillar · not comparable | |
| $45.89 Nov 18, 2026 | $4.03B | — 5-pillar · not comparable | |
| $64.02 Nov 19, 2026 | $12.7B | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held MTHRY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported MTHRY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About MTHRY (Healthcare)
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
Is MTHRY a good stock to buy?
Stock Expert AI does not rate MTHRY buy, sell or hold. M3, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the MTHRY stock price today?
The last price recorded for M3, Inc. (MTHRY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for MTHRY?
Evaluate MTHRY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Not financial advice.
How frequently does MTHRY data refresh on this page?
MTHRY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven MTHRY's recent stock price performance?
(MTHRY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Extensive global network of healthcare professionals on its digital platforms. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MTHRY overvalued or undervalued right now?
(MTHRY) trades at 25.29x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MTHRY before investing?
Before investing in M3, Inc. (MTHRY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding MTHRY to a portfolio?
Key strength of M3, Inc. (MTHRY): Extensive global network of healthcare professionals on its digital platforms. Weigh rewards against risks and diversify. Not financial advice.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 34 figures on this page — 27 from Financial Modeling Prep (FMP), 3 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com